论文部分内容阅读
目的探讨生长激素治疗宫内发育迟缓矮小患儿的临床疗效。方法选择2012年5月—2014年5月来信阳市中医院就诊的40例宫内发育迟缓矮小患儿作为研究对象,随机分别两组,每组20例。对照组给予常规治疗,包括:补充维生素、微量元素及矿物质,营养支持,同时进行运动锻炼和心理安慰;观察组在对照组基础上行生长激素治疗。两组均治疗1年。半年后随访,观察比较两组生长速度(GV)、身高净增、身高标准差分值(Ht SDS)、身高增长率、体质量指数(BMI)、血清促生长因子(IGF-1)及胰岛素样生长因子结合蛋白-3(IGF-BP3)。结果观察组治疗后GV、身高净增、身高增长率及BMI分别为(8.76±1.43)cm/年、(6.71±1.45)cm、(1.33±0.35)cm/月及(16.31±1.42),与对照组(6.74±0.52)cm/年、(4.23±1.02)cm、(0.67±0.21)cm/月、(16.75±1.86)比较,差异均有统计学意义(P<0.05)。治疗后观察组IGF-1与IGF-BP3分别显著高于本组治疗前和对照组治疗后,差异有统计学意义(P<0.05)。结论生长激素对改善宫内发育迟缓患儿身材矮小、低体质量症状效果显著,IGF-1与IGF-BP3对小儿成长发育具有重要作用。
Objective To investigate the clinical effect of growth hormone in the treatment of short stature in children with intrauterine growth retardation. Methods Forty infants with drowned uterus in our hospital from May 2012 to May 2014 were enrolled in this study, and were randomly divided into two groups (20 in each group). Control group were given routine treatment, including: vitamin supplementation, trace elements and minerals, nutritional support, exercise and psychological comfort at the same time; the observation group was treated with growth hormone on the basis of the control group. Both groups were treated for 1 year. After six months follow-up, the growth rate (GV), net height, height standard deviation (Ht SDS), height growth rate, body mass index (BMI), serum pro-growth factor (IGF- Growth Factor Binding Protein-3 (IGF-BP3). Results After treatment, the GV, net height, height growth rate and BMI of the observation group were (8.76 ± 1.43) cm / year, (6.71 ± 1.45) cm and (1.33 ± 0.35) cm / month and (16.31 ± 1.42) There was significant difference between the control group (6.74 ± 0.52) cm / year, (4.23 ± 1.02) cm and (0.67 ± 0.21) cm / month and (16.75 ± 1.86) respectively (P <0.05). After treatment, the levels of IGF-1 and IGF-BP3 in the observation group were significantly higher than those in the control group before treatment and in the control group, respectively (P <0.05). Conclusion Growth hormone has a significant effect on short stature and low body weight symptoms in children with intrauterine growth retardation. IGF-1 and IGF-BP3 play an important role in the growth and development of children.